ArticleNeurology(R) neuroimmunology & neuroinflammation2016
Induction of gut regulatory CD39
Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- FFAR2 activation induces IL-22-dependent intestinal immune responses to suppress CNS autoimmunity.EMBO molecular medicine · 2026Article
- T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances.Frontiers in immunology · 2026Review
- Endoneurial immune interplay in peripheral nerve repair: insights and implications for future therapeutic interventions.Frontiers in neuroscience · 2025Review
- Microbiota modulation by teriflunomide therapy in people with multiple sclerosis: An observational case-control study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Observational
- Efficient enzyme-free method to assess the development and maturation of the innate and adaptive immune systems in the mouse colon.Scientific reports · 2024Article
- The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study.Microbial cell (Graz, Austria) · 2024Article
- Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2023Review
- Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?Therapeutic advances in neurological disorders · 2023Review
- Effect of IL-27, Teriflunomide and Retinoic Acid and Their Combinations on CD4Molecules (Basel, Switzerland) · 2022Article
- The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis.Frontiers in immunology · 2022Review
- Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response.Frontiers in immunology · 2021Article
- ILC3, a Central Innate Immune Component of the Gut-Brain Axis in Multiple Sclerosis.Frontiers in immunology · 2021Review
- Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know.Brain sciences · 2020Review
- Induction of Regulatory Properties in the Intestinal Immune System by Dimethyl Fumarate in Lewis Rat Experimental Autoimmune Neuritis.Frontiers in immunology · 2019Article
- Immunological Aspects of Approved MS Therapeutics.Frontiers in immunology · 2019Review
- Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.Frontiers in immunology · 2019Article
- Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?Auto- immunity highlights · 2018Review
- The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.Brain : a journal of neurology · 2018Review
- Regulatory T cells in multiple sclerosis and myasthenia gravis.Journal of neuroinflammation · 2017Review
- The chicken or the egg dilemma: intestinal dysbiosis in multiple sclerosis.Annals of translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether as an orally delivered treatment, teriflunomide, an inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase approved to treat relapsing forms of multiple sclerosis, could affect gut-associated lymphoid tissue (GALT) immune responses functionally.
methodsC57BL/6 mice were treated orally with teriflunomide and flow cytometric analysis of immune GALT cells performed ex vivo, and adoptive transfer experiments were used to test the protective effects of GALT regulatory T (Treg) cells.
resultsTeriflunomide reduced the percentages of antigen-presenting cells of Peyer patches when compared to controls. Conversely, a significant increase of the relative frequency of CD39
conclusionsOur results identify specific GALT-derived CD39
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.